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Background: To evaluate the utility of the preoperative PET-CT using deformable image registration (DIR) in the
treatment of patients with locally advanced breast cancer and to find appropriate radiotherapy technique for
further adequate treatment of axillary nodal area.
Methods: Sixty-five breast cancer patients who had level II, III axillary or supraclavicular lymph node metastasis on
18F-FDG PET-CT and received postoperative radiotherapy after modified radical mastectomy were enrolled. One
radiation oncologist contoured normal organs (axillary vessels, clavicular head, coracoids process and humeral head)
and involved lymph nodes on PET-CT and simulation CT slices. After contouring, deformable image registration of
PET-CT on simulation CT was carried out. To evaluate the performance of the DIR, Dice similarity coefficient (DSC)
and Center of mass (COM) were used. We created two plans, one was the historically designed three field plan and
the other was the modified plan based on the location of axillary lymph node, and we compared the doses that
irradiated the axillary lymph nodes.
Results: The DSCs for axillary artery, axillary vein, clavicular head, coracoids process and humeral head were 0.43 ±
0.15, 0.39 ± 0.20, 0.85 ± 0.10, 0.72 ± 0.20 and 0.77 ± 0.20, respectively. The distances between the COMs of axillary
artery, axillary vein, clavicular head, coracoids process and humeral head in simulation CT and from PET-CT were
13.0 ±7.1, 20.2 ± 11.2, 4.4 ± 6.3, 3.7 ± 6.7, and 9.5 ± 25.0 mm, respectively. In the historically designed plan, only 57.7%
of level II lymph nodes received more than 95% of prescribed dose and the coverage was improved to 70.0% with
the modified plan (p < 0.01). For level III lymph nodes, the volumes received more than 95% of prescribed dose
were similar in both plans (96.8 % vs 97.9%, p = 0.35).
Conclusion: Deformable image registration of PET-CT on simulation CT was helpful in the identification of the
location of the preoperatively involved axillary lymph node. Historically designed three-field plan was not adequate
to treat the axillary level II lymph node area. Novel treatment technique based on the location of axillary lymph
node from PET-CT using DIR can result in more adequate coverage of nodal area.
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Table 1 Patient characteristics
No. of patients (%)
Involved LN
Level II only 28 (43%)
Level II + III 16 (25%)
Level II + III + SCN 14 (21%)
Level III + SCN 2 (3%)









The type of axillary surgery
Sentinel node biopsy only 11 (16.9%)
ALND (level I + II) 36 (55.4%)
ALND (level I + II + III) 12 (18.5%)
ALND (level I + II) + SCND 6 (9.2%)
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Breast cancer is the second most common cancer in
Korean women [1]. General management for patients
with breast cancer is surgery. Breast conserving surgery and
adjuvant radiotherapy is the standard treatment for early
breast cancer and mastectomy with or without neoadjuvant
chemotherapy for locally advanced breast cancer. Adjuvant
radiotherapy after mastectomy is recommended for pa-
tients with large tumor (> 5 cm) or 4 or more axillary
LN involvement [2]. Tumor cells that have remained in
the locoregional lymphatics and chest wall may be the
source of distant metastasis [3], so optimal irradiation
to these areas is important to improve the tumor con-
trol. The target volume after mastectomy includes the
chest wall and locoregional lymphatics. Postoperative
adjuvant locoregional radiotherapy after mastectomy
showed a survival advantage for women with lymph
node positive breast cancer [4-7].
PET-CT is an emerging diagnostic modality in the man-
agement of most of the malignancies, including breast
cancer. The sensitivity of PET or PET-CT in detecting
axillary lymph node is only 63% [8] but hypermetabolism
of an axillary lymph node in noninfectious condition is
highly suggestive of metastasis [9,10]. There have been
many efforts to use PET or PET-CT image for RT plan-
ning in various tumor sites [11-13]. Addition of PET
image to RT planning can improve the accuracy of target
delineation. Although PET-CT image acquired in the
treatment position is ideal for target delineation, it is not
possible in the treatment of breast cancer because the
mainstream of treatment for breast cancer is surgery and
radiotherapy is given postoperatively. Only preoperative
PET-CT is available and this image cannot be directly
used for RT planning. The possible method to incorporate
the preoperative PET-CT image into RT planning is to
use image registration tool. However, rigid image registra-
tion may be inadequate if there is a positional change,
therefore deformable image registration (DIR) can be
used. DIR has enormous possibilities for its application in
the RT plan [14-17]. Recently, there has been commercial
development of software for DIR.
In this study, we evaluated the utility of the preoperative
PET-CT for radiotherapy using DIR and intended to find
appropriate radiotherapy technique to treat axillary nodal
area in a more adequate manner.
Materials and methods
Patient selection
From January 2009 to January 2011, 65 breast cancer pa-
tients who had level II, III axillary or supraclavicular
lymph node metastasis on whole-body 18F-FDG PET-CT
and received postoperative radiotherapy on chest wall and
regional lymphatics after modified radical mastectomy
(MRM) were enrolled for the present study.The patient characteristics are shown in Table 1. Sixty-
three patients (97%) had level II lymphadenopathy (LAP),
32 patients (49%) had level III LAP and 21 patients (32%)
had supraclavicular LAP. Eighty nine percent of the pa-
tients (58/65) underwent percutaneous needle aspiration
biopsy at the axillary nodal area before surgery and 90% of
the patients (52/58) had nodal metastasis. Among the 6
patients, who showed negative biopsy finding, 5 of them
were confirmed to have nodal metastasis after surgery.
Fifty-four patients (83%) received neoadjuvant chemother-
apy before surgery.
All patients underwent PET-CT at the time of diagnosis.
PET-CT was performed on curved scanner table with both
arms raised above the head. All patients underwent simu-
lation CT after MRM and axillary surgery. The type of
axillary surgery is shown in Table 1. Simulation CT
scan was performed on sloped flat breast board with the
ipsilateral arm raised above the head.
Organ contouring and deformable image registration
PET-CT and simulation CT images were transferred to ra-
diation treatment planning system (Eclips, Varian Medical
System). One radiation oncologist contoured normal or-
gans and involved lymph nodes on PET-CT and simula-
tion CT slices within planning system (Figure 1). The
delineated normal organs were axillary vessels, clavicular
head, coracoids process and humeral head. Target volumes
were delineated on simulation CT according to RTOG
Figure 1 Normal organs were contoured on simulation CT images. Axillary vessels, clavicular head, coracoids process and humeral head
were delineated.
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nodes were contoured only on PET-CT. After contouring,
deformable image registration of PET-CT on simulation
CT was carried out using commercially available intensity
based deformable image registration software (MIM-Vista
version 5.1, MIM software Inc, USA) (Figure 2). Subse-
quently, the normal organs and involved lymph nodes
contoured on PET-CT were transferred to simulation CT.
They were quantitatively compared with the contours de-
lineated on simulation CT with respect to the correspond-
ence. Two methods were employed to evaluate the
performance of the DIR. One was Dice similarity coeffi-
cient (DSC) and the other was Center of mass (COM).
The DSC measures the overlap between two structures and
is represented from 0 (no overlap) to 1 (perfect overlap).
It is defined by the formula; DSC = VsimCT∩VPET-CT/
{(VsimCT + VPET-CT)/2}, where VsimCT is the volume of
contour delineated on simulation CT and VPET-CT is the
volume of contour transferred from PET-CT. We also
measured the COM of each structures contoured on
simulation CT and transferred from PET-CT and calcu-
lated the distance between the COMs of the structures
in simulation CT and the ones transferred from PET-CT
. For axillary vessels, the volumes that expanded 0.5 cm
from axillary vessels were used in measuring DSC and
the distance between the COMs because axillary vessels
were very thin structures.
We also attempted to explore the clinical factors
affecting DSC and the distance between the COMs.Pearson correlation coefficient was used to evaluate
the association.
Radiation technique
All the patients were treated on sloped flat breast board
in supine position with the ipsilateral arm elevated above
the head. The arm was immobilized with individualized
mold.
We created two plans, one was the historically designed
plan and the other one was the modified plan, and
compared the doses that irradiated the lymph nodes. In the
historically designed plan, three beams were used for radio-
therapy, one anterior beam to treat the level II, III and
supraclavicular lymph nodes (Figure 3A) and two tangential
beams to treat the chest wall (Figure 3B). The anterior
beam was angulated to 5 degrees to reduce the dose to
spinal cord and esophagus. Entire chest wall from midline
to mid-axillary line was included in the tangential beams.
Wedge was used to achieve uniform dose distribution. A
single isocenter was employed to minimize matching prob-
lem between the anterior field and the tangent fields. The
isocenter was located at the inferior border of the clavicular
head according to the historical method. The prescribed
dose was 50 Gy at 2 Gy per fraction. The dose to the anter-
ior field was prescribed at a depth of 3 cm.
In the modified plan, beam arrangements were similar to
the historical plan. Tangent beams were same to the histor-
ical plan. For the treatment of anterior field, 90% of the pre-
scribed dose to anterior field was irradiated similarly to the
Figure 2 Representative images after deformable image registration. A: Simulation CT images. B: PET-CT images. C: Fusion images of
deformed PET and simulation CT.
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fied anterior field. The modified anterior field was 1 cm
larger below the junction compared to the historical field
(Figure 3C). Accordingly, it overlapped 1 cm with the tan-
gential field. The dose around the junction is always lower
than the prescribed dose, so to compensate the under-
dose, 10% of the prescribed dose was irradiated to 1 cm
larger field below the junction. In the modified plan,
posterior axillary boost (PAB) field was used (Figure 3D).
After the doses delivered to the anterior field and the
modified anterior field were calculated, the area received
the dose below 90% of the prescribed dose was delineated
and then PAB was performed on this area. The PAB dose
was adjusted depending on the dose distribution.Statistical analysis
Pearson correlation coefficient was used for the analysis of
an association between the variables. We analyzed the as-
sociation between the clinical characteristics such as BMI
(Body mass index) and the performance of DIR. Paired t-
test was used to assess the differences between the vari-
ables. The tests were performed at the 0.05 level of signifi-
cance. SPSS version 12.0 (SPSS Inc., Chicago, IL) was used
for the statistical analysis.
Results
Evaluation of the performance of the DIR
The DSCs for axillary artery, axillary vein, clavicular head,
coracoids process and humeral head were 0.43 ± 0.15
Figure 3 Digitally reconstructed radiographs (DRR) image of each field. A: Anterior field. It is the historically designed field. B: Tangential
fields. They also follow the historically designed fields. C: Modified anterior field. It is 1 cm larger below the junction compared to the historical
field. D: Posterior axillary boost beam. Sky blue line represents the area received the dose below 90% of the prescribed dose.
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0.72 ± 0.20 and 0.77 ± 0.20, respectively (Table 2, Figure 4).
The DSC value was highest for clavicle and lowest for axil-
lary vessels.
The distance between the COMs of axillary arteries in
simulation CT and from PET-CT was 13.0 ± 7.1 mm
(Mean ± 95% confidence interval). Those of the axillary
vein, clavicular head, coracoids process and humeral headTable 2 Mean DSC and the distance between the COMs of str
Axillary artery
DSC*
mean ± 95% CI† 0.43 ± 0.15
Distance between the COMs‡ (lateral direction) (mm)
mean ± 95% CI 11.0 ±7.6
Distance between the COMs (sup.-inf. direction) (mm)
mean ± 95% CI 3.7 ± 2.2
Distance between the COMs (ant.-post. direction) (mm)
mean ± 95% CI 3.7 ± 2.9
Distance between the COMs (3 dimensional) (mm)
mean ± 95% CI 13.0 ± 7.1
* Dice similarity coefficient, † Confidence interval, ‡ Centers of mass.were 20.2 ± 11.2, 4.4 ± 6.3, 3.7 ± 6.7, and 9.5 ± 25.0 mm,
respectively (Table 2, Figure 4). The distance between the
COMs of structures was largest in axillary vessels and
smallest in coracoids process. The distance of COMs for
axillary vessels was largest in lateral direction.
We also evaluated clinical factors affecting DSC and the
distance between the COMs. Because DSCs of axillary
vessels were found to be the smallest among axillaryuctures
Axillary vein Clavicle Coracoid process Humeral head
0.39 ± 0.20 0.85 ± 0.10 0.72 ± 0.20 0.77 ± 0.20
18.4 ± 11.8 2.8 ± 3.7 1.4 ± 3.6 4.8 ± 17.0
3.7 ± 3.0 2.7 ± 4.8 2.4 ± 5.2 5.9 ± 17.5
5.2 ± 4.1 1.7 ± 2. 1.9 ± 2.7 4.5 ± 7.4
20.2 ± 11.2 4.4 ± 6.3 3.7 ± 6.7 9.5 ± 25.0
Figure 4 The graphs show Dice similarity coefficient (DSC) and the distance between the Centers of mass (COMs) of structures. The
error bars represent 95% confidence interval.
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head, the correlations were analyzed between clinical fac-
tors and DSC and the distance between centers of axillary
vessels. Any clinical features did not affect the DSC and
the distance between centers of axillary vessels (Table 3).
The locations of the involved axillary lymph nodes
The length from the lower border of the axillary vessels
to the most inferior point of level II lymph node is rep-
resented in Figure 5. Forty six percent (29 of 63) of axil-
lary lymph nodes were within 1 cm below the lower
border of the axillary vessels and 76% (48 of 63) were
within 2 cm, and 90% (57 of 63) within 3 cm. The max-
imum length from the lower border of the axillary ves-
sels to the most inferior point of level II lymph node
ranged from 1.4 cm from 3.5 cm (median, 1.4 cm).
The depth of level II lymph node was measured
from the surface and is represented in Figure 5. Only
10% (6 of 63) of level II lymph nodes were within 3cm
from the surface and 46% (29 of 63) were within 4 cm,and 84% (53 of 63) were within 5 cm. The maximum
depth of the level II lymph nodes ranged from 2.3 cm
from 6.5 cm (median, 4.2 cm).
The maximum depth of the level III lymph nodes
ranged from 1.9 cm from 5.6 cm (median, 3.4 cm). The
depth of the level III lymph nodes was within 3 cm in
31% (10 of 32), within 4 cm in 84% (27 of 32).
The maximum depth of the supraclavicular lymph
nodes (SCLN) ranged from 1.4 cm from 6.8 cm (median,
3.8 cm). The depth of the SCLN was within 3 cm in 38%
(8 of 21), within 4 cm in 71% (15 of 21). The depth of the
SCLN and axillary lymph nodes was within ±1 cm in 48%
(10 of 21) of patients. The axillary lymph nodes were
located at ≥1 cm shallower or greater in 19% (4 of 21)
and 33% (7 of 21) of patients, respectively.
The dose to the axillary lymph nodes and normal organs
The differences in the dose distribution between the two
plans are summarized in Table 4. Historically designed
plan was not satisfactory with respect to covering the
Figure 5 Location of level II axillary lymph node. A. The
distribution of the maximal length from the axillary vessels to the
level II lymph node. B. The distribution of the maximal depth from
surface to level II lymph node.





BMI* and †DSC of axillary a. 0.74 0.56
BMI and distance between the COMs‡
(axillary a.)
0.00 0.98
Level II volume and DSC of axillary a. −0.11 0.41
Level II volume and distance between the
COMs (axillary a.)
0.24 0.06
Initial weight and DSC of axillary a. 0.01 0.97
Initial weight and distance between the
COMs (axillary a.)
0.18 0.14
Weight loss and DSC of axillary a. −0.18 0.16
Weight loss and distance between the COMs
(axillary a.)
0.24 0.06
BMI and DSC of axillary v. 0.05 0.70
BMI and distance between the COMs
(axillary v.)
−0.22 0.08
Level II volume and DSC of axillary v. −0.17 0.18
Level II volume and distance between the
COMs (axillary v.)
0.16 0.21
Initial weight and DSC of axillary v. −0.04 0.73
Initial weight and distance between the
COMs (axillary v.)
−0.09 0.49
Weight loss and DSC of axillary v. −0.16 0.19
Weight loss and distance between the COMs
(axillary v.)
0.10 0.43
* Body mass index, † Dice similarity coefficient, ‡ Centers of mass.
Table 4 Differences in the dose distribution between the
two plans
Historical plan Modified plan P value
Maximum dose 58.0 ± 1.33 56.4 ± 1.49 <0.01
Level II
Mean D95 45.4 ± 3.3 46.7 ± 2.7 < 0.01
Mean V95 57.7 ± 36.9 70.0 ± 33.6 <0.01
Mean dose 48.3 ± 3.0 49.0 ± 2.2 <0.01
Level III
Mean D95 51.3 ± 2.4 50.6 ± 2.1 <0.01
MeanV95 96.8 ± 14.7 97.9 ± 8.4 0.35
Mean dose 52.5 ± 1.9 51.9 ± 1.5 <0.01
Lung
V5 38.6 ± 8.4 40.9 ± 8.3 <0.01
V10 31.4 ± 7.7 31.8 ± 7.7 <0.01
V20 27.8 ± 7.5 28.0 ± 7.5 <0.01
Mean dose 14.3 ± 3.4 14.3 ± 3.4 0.22
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lymph nodes received more than 95% of prescribed dose.
Level III lymph nodes received much higher dose than
level II lymph nodes, so 96.8% of the volume received
more than 95% of prescribed dose. Improvement in the
coverage of level II lymph node was observed with the
modified plan. The volume received more than 95% of
prescribed dose (V95) increased from 57.7% to 70.0% sta-
tistically significantly (p < 0.01). Furthermore, the mean
dose to level II lymph node increased. V95s for level III
lymph node were similar in both plans (p = 0.35). Al-
though mean dose to level III lymph node in the modified
plan was lower than in the historical plan, the doses in the
two plans were more than the prescribed dose. Maximum
dose decreased in the modified plan compared to the his-
torical plan (p < 0.01). Ipsilateral lung volumes received 5
Gy, 10 Gy and 20 Gy increased statistically significantly in
the modified plan. Figure 6 shows representative dose dis-
tribution and dose volume histogram of axillary LNs and
ipsilateral lung in both plans.
Discussion
In the treatment of breast cancer, locoregional RT has
been proven to improve overall survival in women with
Figure 6 Representative dose distribution and dose volume histogram (DVH) of axillary lymph nodes and ipsilateral lung in both
plans. A. Dose distribution in the historical plan at the level of level II lymph node. Orange colored area is initially involved level II lymph node
area. Green line shows the area received 96% of the prescribed dose. B. Dose distribution in the modified plan. C. DVH of axillary LNs and
ipsilateral lung in the two plans. The dose irradiated to the level II lymph node increased in the modified plan. The dose to level III lymph node
in the modified plan was lower than in the historical plan but the doses were more than prescribed dose in both plans. The maximum dose
decreased in the modified plan.
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for breast cancer is usually given postoperatively, so RT
technique is standardized irrespective of the initial loca-
tion of the tumor. The existence of residual disease after
initial treatment may lead to distant dissemination [3].
The accuracy of the DIR
In this study, we used DSC and the distance between
COMs to evaluate the performance of DIR. The DSC was
low for axillary vessels. There are several reasons in low
DSC. First, simulation CT for the radiotherapy was ac-
quired with a sloped flat breast board, whereas PET-CT
was acquired with a curved scanner table. The arm pos-
ition was largely changed during the deformation. Second,the locations of axillary vessels might be changed after the
removal of enlarged axillary lymph nodes around the axil-
lary vessels at the time of surgery. Third, DSC is not very
useful for very small volumes [18]. The volume of axillary
vessels is so small that no overlap in a few slices results in
a low DSC.
The distance between the COMs for structures showed
similar pattern. The distance between the centers of
axillary vessels was largest among the structures and it
was prominent in lateral direction. Usually axillary ves-
sels are present in three or four CT slices and vessels
might be either longer or shorter according to the cut-
ting angle. Some difference between the lengths of the
axillary vessels in any CT slice can change the locations
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tion, which can lead to the large value in the distance
between the COMs.
The DSCs of bony structures were higher than 0.7. It
was proposed by Zijdenbos et al. that a coefficient larger
than 0.70 represents a good overlap [19]. This was ac-
complished in bony structures. The distance between
the COMs for bony landmarks such as clavicle, cora-
coids process is relatively small but high in humeral
head. It may be influenced by change of arm position
between PET/CT and simulation CT. In consideration
of good results of bony structures, the DIR of initially
involved axillary lymph nodes is generally acceptable.
PET-CT
PET-CT is a useful diagnostic tool for the evaluation of
breast cancer, especially locally advanced breast cancer.
PET or PET-CT have lower sensitivity and specificity than
sentinel LN biopsy, therefore they cannot replace sentinel
LN biopsy [8,9]. However, the positive predictive value of
PET or PET/CT was 84%, so hypermetabolism of an axil-
lary lymph node in noninfectious condition is highly sug-
gestive of metastasis [8]. As Level III and supraclavicular
LN area are not usually dissected in routine axillary LN
dissection, it is very important to include these preopera-
tively detected LN areas in radiotherapy. In our study,
80% of patients were confirmed to have axillary lymph
node metastasis preoperatively and 8% of patients were
confirmed postoperatively. PET-CT image showing hyper-
metabolism in axillary lymph node suggests high possibil-
ity for the presence of a pathologic lymph node. Such
nodal areas should be treated adequately to eradicate
possible microscopic residual disease.
The location and the coverage of axillary lymph node
The depth of axillary LN and SCLN was comparable to
other study measuring depth of lymph nodes [20]. Bentel
et al. showed the median maximum depth of axillary LN
and SCLN were both 4.3 cm and the depth of axillary
LN was less than 3 cm in 16% (8 of 49) of patients. The
median maximum depth of level II axillary lymph node
and SCLN was 4.1 cm and 3.8 cm, respectively in this
study. And the depth of axillary level II LN was within 3
cm in 10% (6 of 63) in this study. However, the location
of lymph nodes was estimated based on the location of
the vessels, scar, or clips on simulation CT in Bentel’s
study. It may be helpful to estimate more accurate initial
location of lymph nodes to use DIR of preoperative
PET/CT.
Recently published contouring atlas defined that caudal
border of axillary level III LN is 1 cm caudal to the axillary
vessels [21]. However, only 46% of axillary lymph nodes
were within 1 cm below the lower border of the axillary
vessels in this study. Therefore we expect that our datacan be integrated into further guideline of contouring
volumes.
When the junction between anterior beam and tangen-
tial beams is located at the inferior end of the clavicular
head, lymph nodes near the junction receive lower dose
than the prescribed dose. To overcome this underdose
around the junction, the junction may be moved inferiorly
than the lower end of the clavicular head, but it can result
in overdose to the lung. Matchline shift during the course
of treatment is the most common method to reduce
underdose area, but there is a possible uncertainty and it
is time-consuming. By using half-beam technique and
modified anterior field weighted 10% of monitor unit, we
could improve the coverage of level II lymph node without
increasing maximum dose. We suggest that modified
technique using modified anterior field weighted 10% of
prescribed dose can be an alternative way to reduce
underdose around the junction.Conclusion
Deformable image registration of PET-CT on simulation
CT was acceptable in the identification of the location of
the preoperatively involved axillary lymph node. Historic-
ally designed three field technique was not adequate to
treat the axillary level II lymph node area. New treatment
technique based on the location of axillary lymph node
from PET-CT using DIR can result in more adequate
coverage of nodal area.
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